AstraZeneca is trading at $167.11, up 3.14% in pre-market after announcing a strategic collaboration with AI-focused biotech company insitro. - The partnership, potentially worth up to $1.5 billion, aims to leverage artificial intelligence for drug discovery and licensing in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. - The company also exceeded quarterly earnings expectations, reporting $2.63 in EPS versus the $2.50 consensus estimate.